Rueil Malmaison, France

Vincenzo Rovei


Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 1991-1993

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Vincenzo Rovei: Innovator in Pharmaceutical Chemistry

Introduction

Vincenzo Rovei is a notable inventor based in Rueil Malmaison, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 6 patents to his name, Rovei's work continues to impact the industry.

Latest Patents

Among his latest patents, Rovei has developed 3-aryl oxazolidinone compounds and their therapeutic uses. These derivatives are characterized by specific chemical formulas, where R1 denotes C1-C4 alkyl, X can be oxygen or methylene, and R2 can be C1-C4 alkyl or CF3. Additionally, R3 represents a CH2R4 group, with R4 being a pentagonal or hexagonal aromatic heterocyclic group that may include nitrogen atoms. His innovative work also includes the preparation of these derivatives through condensation processes.

Career Highlights

Rovei's career is marked by his dedication to advancing pharmaceutical research. His innovative approaches have led to the creation of compounds that hold promise for various therapeutic applications. His expertise in the field has established him as a respected figure among his peers.

Collaborations

Rovei has collaborated with notable colleagues, including Francois X Jarreau and Jean-Jacques Koenig. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Vincenzo Rovei's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications, showcasing the importance of innovation in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…